Silver Book Fact

Use of pneumonia vaccine in children reduced rates in adults age 65+

Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4; invasive pneumococcal disease rates in unvaccinated individuals age 65 and older fell by 18%.

Whitney C, Farley M, Hadler J, Harrison L, et al. Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine. NEJM. 2003; 348(18): 1737-46. http://www.nejm.org/doi/full/10.1056/NEJMoa022823

Reference

Title
Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine
Publication
NEJM
Publication Date
2003
Authors
Whitney C, Farley M, Hadler J, Harrison L, et al
Volume & Issue
Volume 348, Issue 18
Pages
1737-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Value of polio eradication
    Eradication of polio is estimated to produce savings to governments of $1.5 billion per year.  
  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.  
  • Hospitalizations from flu increase with age
    People age 65+ account for 50% of flu hospitalizations.  
  • Vaccines cost ~$50 per healthy life year saved
    Most vaccinations cost less than $50 per healthy life year saved. In contrast, treating hypertension costs between $4,340 and $87,940 per healthy life year saved.  
  • Shingles vaccine could improve QALY and save money
    Vaccination of 1 million people age 60 and over with the shingles vaccine would result in 11,919 non-discounted and 8,782 discounted QALYs (quality of life years) gained and save around…